Navigation Links
Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
Date:3/14/2011

sing Humalog® as a comparator in which active dose titration will occur in the first two months after randomization followed by three months of relatively stable dosing.  In these studies, Biodel plans to evaluate efficacy using HbA1c as well as measures of postprandial glucose profiles.  If the results of the Phase 2 testing are successful, the company plans to launch Phase 3 pivotal studies required for approval in 2012 rather than its previous guidance of 2013.

"We look forward to obtaining initial clinical data for BIOD-105 and BIOD-107," said Dr. Alan Krasner, Chief Medical Officer of Biodel.  "Based on pharmacokinetic data obtained in the diabetic swine model, these formulations appear to be very rapidly absorbed, similar to rates of absorption seen with the previously studied Linjeta™ formulations.  Based on last year's clinical data from related formulations BIOD-102 and BIOD-103, we anticipate improved injection site tolerability with BIOD-105 and BIOD-107.  We were very pleased with our end of review meeting with the FDA in which they confirmed study details including the use of Humalog® as a comparator in future clinical trials.  The FDA also confirmed that data from the development program for the new formulations would be classified as a Class 2 resubmission with a 6 month review time."

"We have identified two new formulations with commercial target product profiles that appear to be superior to any of our previous ultra-rapid-acting human insulin drug candidates," said Dr. Errol De Souza, president and CEO of Biodel.  "By achieving our candidate selection milestone and receiving constructive feedback from the FDA during our end of review meeting, we have accelerated the clinical development program of these formulations and plan to initiate Phase 1 clinical testing this month and could initiate Phase 3 testing before the end of 2012."

Biodel now expects to complete the Phase 1 stud
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
4. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
5. Biodel Reports First Quarter Fiscal Year 2011 Financial Results
6. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
7. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
8. Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer
9. Biodel Reports Fourth Quarter and Fiscal Year 2010 Financial Results
10. Biodel Reports New Findings from Key Programs at Diabetes Technology Meeting
11. Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Utah , Aug. 28, 2015  Today, in ... Prevention,s (CDC) Contact Lens Health Week, 1-800 Contacts is ... has found that contact lens wearers who do not ... greatest risk for eye infections. Most ... their lenses, but a clean lens case is sometimes ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Developed by Pharmacia & Upjohn in ... which effectively reduces intraocular pressure. As the first ... the trade name of Xalatan) entered ...
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
Breaking Medicine Technology:1-800 Contacts Shares Tips on How to Clean Lens Cases 2China Latanoprost Market Investigation Report 2015-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5
... BIOD ) announced today the retirement of Dr. ... is a co-founder of Biodel and will remain a member ... chairman, president and chief executive officer from its founding in ... was named the company,s president and chief executive officer and ...
... 2010 Reportlinker.com announces that a new ... catalogue: Asia-Pacific Markets for ... 2011 http://www.reportlinker.com/p0339835/Asia-Pacific-Markets-for-Cardiac-Rhythm-Management-Electrophysiology--Ablation-Devices-2011.html ... Pacific markets for cardiac rhythm management (CRM), ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 2Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 3Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 4Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 5Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 6Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 7Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 8Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 9Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 10Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 11Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 12Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 13Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 14Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 15Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 16Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 17Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 18Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 19Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 20Reportlinker Adds Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 21
(Date:8/28/2015)... ... August 28, 2015 , ... The Kentucky State Department of ... for the position they are applying for, they are unable to pass the initial ... considering altering drug testing policies in order to be able to hire long-term, skilled ...
(Date:8/28/2015)... ... August 28, 2015 , ... For Dallas, the time is nearing for the ... USPI Tenet Health. , The American Heart Association hosts their well-known Heart Walk to ... that together, a difference can be made. Walkers can participate in the cause and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual ... Brain Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an ... , “With the help of the medical community and the University of Illinois ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, ... fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch ... CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in ... should begin with the employer and employees getting together for meaningful group meetings. ...
Breaking Medicine News(10 mins):Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... (EEG) test may hold the key to predicting ... drugs, particularly those related to psychiatric conditions. ... Clinical Neurophysiology , and now posted online, engineering ... machine learning to EEG patterns and successfully predicted ...
... ophthalmic pathologist at St. Michael,s Hospital, has won the prestigious ... of Medicine. Dr. Ycel received the $50,000 award for ... may lead to new treatments for glaucoma and eye tumours. ... has no lymphatics, the channels responsible for pumping fluid and ...
... you less upset about making errors, according to a ... journal of the Association for Psychological Science. The researchers ... while participants made mistakes on a test. Those who ... prominent response to mistakes than those who hadn,t. ...
... Arbor, Mich. A brief, motivational talk in the emergency ... peer violence or problems due to drinking, according to a ... Journal of the American Medical Association . ... work of University of Michigan Health System researchers who immersed ...
... a common blood disorder characterized by low hemoglobin levels, ... cancer. But researchers at Tel Aviv University have discovered ... hemoglobin levels can actually indicate a potential for colon ... Inbal Goldshtein, who works with Dr. Gabriel Chodick and ...
... Reporter , TUESDAY, Aug. 3 (HealthDay News) -- Foreign-born ... medical degrees abroad performed as well or better than ... analyzed records on nearly 250,000 patients hospitalized for a ... 2003-2006. The study included more than 6,100 doctors, including ...
Cached Medicine News:Health News:EEG predicts response to medication for schizophrenia 2Health News:EEG predicts response to medication for schizophrenia 3Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 2Health News:University of Michigan study: Pep talk to teens in the ER helped reduce violence, alcohol misuse 3Health News:Is your hemoglobin 'trending'? 2Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 2Health News:Foreign-Trained Doctors As Good As U.S.-Trained Counterparts 3
For the quantitative determination of Glucose in serum. Endpoint reaction (NAD -> NADH) measured at 340 nm. Linearity: 600 mg/dl. Liquid working reagent prepared with simple 1:9 dilution....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
g-GT Liquid Reagent (Kinetic Method). Wavelength: 405 nm. Linear range: 0-200 U/mL. Prepare Working Reagent in the ratio of 5 parts R1 to 1 part of R2, (i.e., 50 mL R1 and 10 mL R2)....
Intended for the quantitative determination of calcium in serum. Endpoint Reaction. Reaction complete within one minute, color developed is stable for 30 minutes. Wavelength: 570 nm. Linearity: 16 mg...
Medicine Products: